SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is currently trending due to its exceptionally low public float and high insider ownership, drawing intense comparisons to recent high-flying SPACs like AFJK. The community is highly bullish, anticipating significant price appreciation as a potential business combination announcement approaches for this US-based SPAC. Traders are actively discussing its potential for explosive moves driven by supply scarcity, aligning with patterns observed in other low-float market plays.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending due to the recent FDA approval of NEREUS (tradipitant), marking the first new motion sickness drug in over four decades. The community is actively discussing its potential to alleviate GLP-1 induced nausea, viewing this as a significant market opportunity and a catalyst for potential buyouts. While some initially expressed mixed reactions to price action, many believe the stock's long-term value and additional pipeline catalysts are not yet fully reflected.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending amid a contentious and repeatedly postponed shareholder vote on increasing authorized shares, sparking intense debate over its future funding and growth strategy. Bulls anticipate significant, often classified, government contracts and strategic benefits from the Ask Sage acquisition, viewing current price movements as short-term manipulation. Conversely, skeptics express frustration with management, citing a lack of tangible contract announcements and fearing potential dilution, leading to a polarized community discussion.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending due to widespread discussion around year-end tax loss selling and persistent selling from early investors, which is currently driving significant downward pressure. Community sentiment remains sharply divided, with some seeing current levels as a compelling buying opportunity given the company's profitability and growth, while others emphasize ongoing dilution concerns and a challenging market backdrop.

Aimei Health Technology Co., Ltd. is a blank check company, which engages in entering a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The company was founded on April 27, 2023 and is headquartered in New York, NY.

Aimei Health Technology Co Ltd

Aimei Health Technology Co Ltd (AFJK) is trending as traders speculate on a classic "China IPO squeeze" due to its notably low float and thin share structure. The community is actively discussing its highly volatile, casino-like movements, frequent trading halts, and comparing its potential for rapid price swings to similar recent Chinese tickers.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending amidst intense speculation regarding an unconfirmed FDA decision on its relacorilant drug for Cushing's Syndrome, with community chatter divided between rumored rejection causing panic selling and calls to buy the dip. The immediate uncertainty around this key pipeline asset, alongside its existing revenue-generating drug Korlym and other promising indications like ovarian cancer, fuels a volatile debate among investors.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending amidst mixed analyst sentiment driven by concerns over crypto trading volumes, despite a strong 2025 performance. The community is buzzing with frustration over app glitches and modest rewards from recent holiday giveaways, fueling discussions about the platform's reliability and marketing approach. Investors are keenly watching how its crypto correlation and new ventures like prediction markets will shape its near-term outlook.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf (WULF) is trending amidst diverse community sentiment following its successful closing of a $1.3 billion project-level financing for a major AI/HPC data center, an event bulls view as a strong validation of its strategic pivot. While supporters see this and recent zoning approvals as foundational for future growth and a buying opportunity, others express frustration over persistent price weakness, attributing it to broader market volatility and perceived manipulation.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending as investors eagerly await an FDA decision on its AXS-05 supplemental NDA for Alzheimer's disease agitation, viewed as a significant catalyst for an underserved market. This anticipation is fueled by consistently strong and growing prescription numbers for Auvelity in major depressive disorder, reflecting robust commercial execution. The company's expanding CNS pipeline and positive analyst sentiment continue to reinforce its perceived long-term value within the biopharmaceutical sector.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is currently experiencing a surge in attention fueled by high expectations for its upcoming earnings report, with the community anticipating strong revenue growth driven by its high-margin drug Recorlev. Investors are also keenly focused on the company's pathway to sustained profitability and the long-term potential of its pipeline, particularly the promising XP-8121, which analysts believe could achieve blockbuster status. This positive outlook is supported by recent analyst target upgrades and a perceived de-risked profile, positioning Xeris for significant growth within the biopharma sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Revenue growth is explosive but inconsistent, losses remain deep, and valuation far exceeds listed peers on a price-to-sales basis.</li><li>High short interest, though easing from peaks, leaves ASTS vulnerable to sharp volatility or a short squeeze if launches or partnerships deliver positive surprises.</li><li>Retail sentiment is bullish, shorts remain elevated, but analysts warn that valuation risk outweighs near-term upside despite the upcoming BlueBird 6 launch.</li></ul>While speculation swirls around Elon Musk–owned SpaceX’s potential IPO, another space stock quietly delivered a record rally—even as fundamental challenges lingered.&nbsp;<a href="https://stocktwits.com/symbol/ASTS">AST SpaceMobile’s stock</a> had a stellar year, rising to an all-time high of $102.97 despite the satellite communications company experiencing delays in building and launching satellites.The company is under pressure to scale up quickly as competition breathes down its neck, while the capital-intensive nature of its business has put pressure on its liquidity.<h2 class="st-heading-2">ASTS’s BlueBird 6 Hiccup</h2>The launch of the first of ASTS’s next-generation BlueBird 6 satellite — its next significant catalyst — has been pushed back from the originally planned Dec. 15 to Dec. 21. The Indian Space Research Organisation (ISRO), which has been managing the launch, has reportedly&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://timesofindia.indiatimes.com/science/isros-bluebird-6-launch-rescheduled-to-december-21-heaviest-us-satellite-to-boost-global-broadband-in-major-indo-us-mission/articleshow/125959451.cms">communicated</a> the delay, citing prolonged prelaunch activities.ASTS, meanwhile, confirmed on its X handle that BlueBird 6 was encapsulated and handed off to the launcher on Dec. 6 for liftoff, and that the exact December launch date will be announced in the coming days.“This launch marks the beginning of our launch campaign, with a launch every forty-five days on average during 2026,” the company said.<img src="https://news.stocktwits-cdn.com/Screenshot_2025_12_15_at_5_18_30_AM_png_3339d361b3.webp" alt="Screenshot 2025-12-15 at 5.18.30 AM.png">BlueBird 6 is the first of ASTS’s next-generation satellites. According to the company:<blockquote>“When launched, it will feature the largest commercial phased array in low Earth orbit at nearly 2,400 square feet. This represents a 3.5 times increase in size over BlueBirds 1-5 and supports 10 times the data capacity.”</blockquote><h2 class="st-heading-2">ASTS’s Risk-Reward Profile</h2>AST SpaceMobile operates in a high-growth, high-risk industry, with the company touring its total addressable market (TAM) at $1 trillion and potential subscribers at about 3 billion.&nbsp;&nbsp;Its revenue rose a whopping 1,240% year-over-year to $14.74 million in the third quarter ended on Sept. 30, 2025, yet it missed the consensus estimate. The topline has trailed expectations in each of the past four quarters. It continues to rake in huge losses as operating expenses rise.&nbsp;<img src="https://news.stocktwits-cdn.com/ASTS_Quarterly_Revenue_Losses_png_85a689024e.webp" alt="ASTS_Quarterly_Revenue_Losses.png">Source:&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://fiscal.ai">Fiscal.ai</a>ASTS generates revenue through wholesale service agreements with mobile network operators such as AT&amp;T, Verizon, Vodafone, etc, with carriers providing satellite service as an add-on to their plans. Revenue is shared equally between the two parties. It also gets revenue from federal contracts. The company has the potential to&nbsp;generate subscription-based revenue by providing seamless space-based voice, data, and video to users in&nbsp;a dead zone.<h2 class="st-heading-2">A Pricer Stock</h2>Compared with its publicly listed rivals, ASTS commands a hefty price-to-sales (P/S) valuation. Its P/S ratio is 124.84 compared to 32.61 for Globalstar and 2.23 for Iridium communication. SpaceX’s valuation, by the same measure, would be 25.1 times, considering a valuation of $400 billion, according to Morgan Stanley’s August report. Musk-led&nbsp;SpaceX’s valuation based on the latest insider stock sales is reportedly $800 billion, but it is also said to be&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/did-musk-just-confirm-space-x-ipo-is-happening/cLIxPawREVU">aiming</a> for a $1.5 trillion valuation if it goes public.<img src="https://news.stocktwits-cdn.com/ASTS_stock_return_png_e4afb84d23.webp" alt="ASTS stock return.png">Source: KoyfinThe short interest in&nbsp;ASTS’ stock is relatively high, although the short percent has declined from the March peak of over 21%, making it an ideal candidate for a squeeze if there is positive news flow down the line.<img src="https://news.stocktwits-cdn.com/ASTS_Short_Interest_png_954d764e43.webp" alt="ASTS Short Interest.png">Source: Koyfin<h2 class="st-heading-2">Retail Upbeat, Analysts Wary</h2>AST SpaceMobile stock elicited a ‘bullish’ reaction from among Stocktwits’ retail users as of early Monday. Retail mood, however, tempered from an ‘extreme bullish’ stance seen a week ago.<figure class="image"><img style="aspect-ratio:712/441;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_15_at_6_04_26_AM_png_e0c9cf60f1.webp" alt="Screenshot 2025-12-15 at 6.04.26 AM.png" width="712" height="441"></figure>&nbsp;&nbsp;According to Koyfin, the average analyst price target for AST SpaceMobile stock is $71.51, implying a downside of nearly 7% from current levels. More than half of the analysts covering the stock either remain on the sidelines or are bearish.Bearish analysts are mainly concerned about valuation. When Barclays double-downgraded the stock in mid-October, the firm said the direct-to-cellular segment would be a "very attractive opportunity" and that AST has key assets to succeed, The Fly reported. Still, the stock's valuation "has become excessive,” the firm said.With stock pulling back from its October peak and bottoming in late November, Scotiabank upgraded it to ‘Sector Perform’ from ‘Underperform’ and maintained the price target at $45.60. But since then, the stock has trended higher.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rivian-2025-is-a-comeback-year-but-can-its-stock-continue-to-outrun-tesla/cLeEULJRE8o">For Rivian, 2025 Is A Comeback Year — But Can Its Stock Continue To Outrun Tesla With Big AI Bets?</a>

Launch of the first of AST SpaceMobile’s next-generation BlueBird satellite has been pushed back.

AST SpaceMobile’s Extraordinary Year Didn’t Come Easy — The Next Satellite Launch May Decide Whether This Rally Has Real Legs

ASTS stock surged to record highs despite delays, losses, and bloated valuation, as retail optimism clashes with analyst caution ahead of the crucial BlueBird 6 launch.

Equity

ASTS stock surged to record highs despite delays, losses, and bloated valuation, as retail optimism clashes with analyst caution ahead of the crucial BlueBird 6 launch.


<ul class="summary-bullets"><li>The launch follows closely on the heels of Rocket Lab’s recent HASTE mission.</li><li>If successful, the ‘Follow My Speed’ mission will mark Rocket Lab’s 18th launch in a single year.</li><li>Rocket Lab stock traded over 4% higher in Thursday’s premarket.&nbsp;</li></ul>Rocket Lab Corp. (RKLB) announced on early Thursday that it is gearing up for the Electron rocket launch in under 48 hours after its earlier mission, demonstrating its rapid-response capability in the commercial space sector.This launch follows closely on the heels of Rocket Lab’s recent HASTE mission, which marked the company’s 75th overall flight.<h2 class="st-heading-2">Launch Timing and Client&nbsp;</h2>The upcoming mission, dubbed ‘Follow My Speed,’ is slated to lift off on November 20 from Rocket Lab’s Launch Complex 1 in New Zealand. The rocket will carry a single, confidential commercial satellite.&nbsp;<a href="https://stocktwits.com/symbol/RKLB">Rocket Lab’s stock</a> traded over 4% higher in Thursday’s premarket. On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory amid ‘normal’ message volume levels.&nbsp;<figure class="image"><img style="aspect-ratio:931/106;" src="https://news.stocktwits-cdn.com/Screenshot_2025_11_20_054947_png_3224b28764.webp" alt="RKLB’s Sentiment Meter and Message Volume as of 05:45 a.m. ET on Nov. 20, 2025 | Source: Stocktwits" width="931" height="106"><figcaption>RKLB’s Sentiment Meter and Message Volume as of 05:45 a.m. ET on Nov. 20, 2025 | Source: Stocktwits</figcaption></figure>If successful, this mission will mark Rocket Lab’s 18th launch in a single year, surpassing its previous record of 16 missions. The proximity in timing, less than 48 hours between flights, underscores the company’s growing global reach, using launch pads in both hemispheres.By executing back-to-back missions within a tight timeframe, the company is signaling its readiness to serve commercial customers with time-sensitive needs.<h2 class="st-heading-2">BofA Raises Price Target&nbsp;</h2>On Wednesday, BofA raised its 12-month price target on Rocket Lab to $50, up from its previous $30, according to TheFly. The increase stems from BofA’s conviction that consolidation in the space sector will favor a few large players.&nbsp;The firm said the market is likely to evolve into a ‘winner-take-most’ environment, where strategic vision and integration strength will determine who comes out on top.Rocket Lab offers rocket launches, spacecraft, and satellite hardware for commercial, government, and national security customers. Its Electron vehicle is a small orbital rocket, while its HASTE system supports hypersonic test flights for the U.S. and partner countries.RKLB stock has gained over 71% in 2025 and over 116% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/jobs-data-disruptions-put-fed-in-tight-spot/cLPABllRE9S">Jobs Data Disruptions Put Fed In Tight Spot Weeks Before Crucial December Rate Call</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Rocket Lab USA Inc.

Rocket Lab Plans Second Mission In 48 Hours – RKLB Stock Rises Premarket

The launch follows closely on the heels of Rocket Lab’s recent HASTE mission.

The upcoming mission, dubbed ‘Follow My Speed,’ is slated to lift off on November 20 from Rocket Lab’s Launch Complex 1 in New Zealand. 

JEDI
Drone & Modern Warfare ETF

Feed

News

Sentiment

Fundamentals

Info

Latest JEDI News

JEDIDrone & Modern Warfare ETF